Until 2025, a "GLP-1 pill" meant Rybelsus, a diabetes drug at modest doses with strict empty-stomach rules. The Wegovy pill (high-dose oral semaglutide) was approved on December 22, 2025 for weight management, and Foundayo (orforglipron) followed as the first non-peptide GLP-1 agonist, with no food or water restrictions. In the US, Novo Nordisk then moved its diabetes pill to the Ozempic name: Ozempic tablets were approved on February 4, 2026 and launched nationwide on May 4, 2026, and all three Rybelsus strengths are listed as "To Be Discontinued" in FDA's drug shortage database.
Oral options are not the only needle-free route; some people also ask about GLP-1 patches.
Direct answer: Three GLP-1 pills are on the US market as of November 2026: Foundayo (orforglipron), 0.8–17.2 mg daily with no food restriction, 11.1% mean weight loss at 17.2 mg over 72 weeks (2.1% on placebo); the Wegovy pill (semaglutide), 1.5–25 mg daily with a strict empty-stomach + 30-minute fast, 13.6% at 25 mg over 64 weeks (2.4% on placebo); and Ozempic tablets (semaglutide), 1.5–9 mg daily for type 2 diabetes only, replacing Rybelsus (3–14 mg) in the US. Foundayo wins on convenience; oral Wegovy at top dose still produces more weight loss; injectable GLP-1s (Wegovy injection, Zepbound) remain more effective than any pill.
Every FDA-Approved GLP-1 Pill in the US (November 2026)
Three GLP-1 pills can be started in the US today: the Wegovy pill and Foundayo for weight loss, and Ozempic tablets for type 2 diabetes. Rybelsus is being phased out. Prices are manufacturer self-pay prices checked November 4, 2026.
| Pill | Maker | FDA indication | Daily doses | How it's taken | Typical self-pay cost (source) |
|---|---|---|---|---|---|
| Wegovy pill (semaglutide) | Novo Nordisk | Weight loss and maintenance (obesity, or overweight plus a weight-related condition); lowers major cardiovascular event risk in adults with established heart disease | 1.5 → 4 → 9 → 25 mg, 30 days per step | Morning, empty stomach, up to 4 oz water; wait 30 min before food, drink or other pills | $149/month (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) (NovoCare) |
| Foundayo (orforglipron) | Eli Lilly | Weight loss and maintenance (same criteria) | 0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg, 30+ days per step | Any time, with or without food | $149/month (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9–17.2 mg); 2.5/5.5 mg prices temporary through Dec 31, 2026 (LillyDirect) |
| Ozempic tablets (semaglutide) | Novo Nordisk | Type 2 diabetes (blood sugar, cardiovascular risk). Not for weight loss | 1.5 (30-day starter) → 4 → 9 mg | Same as Wegovy pill | From $149/month, varies by dose (NovoCare Pharmacy) |
| Rybelsus (semaglutide) | Novo Nordisk | Same as Ozempic tablets; being discontinued in the US | 3 → 7 → 14 mg | Same as Wegovy pill | Remaining stock only |
Dosing and indications: Wegovy, Foundayo and Ozempic tablets/Rybelsus prescribing information.
Is there a tirzepatide pill? No oral tirzepatide is FDA-approved; Mounjaro and Zepbound are injections. Foundayo is Lilly's pill, but it is a different, GLP-1-only molecule. No generic oral semaglutide is approved in the US either.
Which GLP-1 Pills Work for Weight Loss?
Only two GLP-1 pills are approved for weight loss: the Wegovy pill and Foundayo. In their label trials, the Wegovy pill 25 mg produced 13.6% average weight loss at 64 weeks and Foundayo 17.2 mg produced 11.1% at 72 weeks.
| Weight-loss pill (top dose) | Trial length | Mean weight change | Placebo | Source |
|---|---|---|---|---|
| Wegovy pill 25 mg | 64 weeks | -13.6% | -2.4% | Wegovy label, Study 7 (OASIS 4) |
| Foundayo 17.2 mg | 72 weeks | -11.1% | -2.1% | Foundayo label, Trial 1 |
| Foundayo 9 mg | 72 weeks | -8.3% | -2.1% | Foundayo label, Trial 1 |
Ozempic tablets and Rybelsus are lower-dose diabetes pills; weight loss on them is a side effect, not an approved use. Other prescription weight-loss tablets exist, but they are not GLP-1 drugs.
The Three FDA-Approved GLP-1 Pills
| Pill | Active ingredient | First approved | Indication | Available doses |
|---|---|---|---|---|
| Foundayo | Orforglipron | April 2026 | Chronic weight management | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg daily |
| Oral Wegovy | Semaglutide | December 2025 | Chronic weight management | 1.5, 4, 9, 25 mg daily |
| Ozempic tablets | Semaglutide | February 2026 | Type 2 diabetes | 1.5, 4, 9 mg daily |
| Rybelsus (being discontinued in the US) | Semaglutide | September 2019 | Type 2 diabetes | 3, 7, 14 mg daily |
The Wegovy pill, Ozempic tablets and Rybelsus all contain the same molecule — semaglutide. Foundayo uses a different molecule (orforglipron), the first small-molecule non-peptide GLP-1 receptor agonist. The newer semaglutide formulation once expected to rebrand Rybelsus is now on the market as Ozempic tablets, launched May 4, 2026, and Rybelsus is being discontinued in the US. They share one FDA label, which says they "are not substitutable on a mg-to-mg basis": Rybelsus 7 mg equals Ozempic tablets 4 mg, and 14 mg equals 9 mg. Outside the US, Rybelsus is still the brand name.
How GLP-1 Pills Work
All three drugs activate the GLP-1 receptor — the same target hit by Wegovy and Ozempic injections. Once activated, the receptor:
- Slows gastric emptying
- Increases satiety and quiets food noise
- Triggers glucose-dependent insulin release
- Suppresses glucagon
- Reduces appetite via brain receptors
The challenge for peptide GLP-1s like semaglutide is that the stomach normally destroys peptides before they reach the bloodstream. The Wegovy and Ozempic (formerly Rybelsus) pills solve this with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), an absorption enhancer that protects semaglutide and helps it cross the stomach lining — but only on a completely empty stomach.
Orforglipron sidesteps the problem entirely: it is not a peptide, so stomach acid doesn't destroy it. No SNAC needed, no fasting required.
Foundayo (Orforglipron) — The New One
The most consequential GLP-1 launch of 2026. Eli Lilly's small-molecule GLP-1 agonist secured FDA approval in April 2026 as the first oral GLP-1 with no food, water, or timing restrictions. Self-pay pricing and savings options are covered in our Foundayo coupon guide.
Dosing
Titration approach:
- Start at 0.8 mg daily for at least 30 days
- Step up after at least 30 days on each dose: 2.5 mg → 5.5 mg, then 9 mg → 14.5 mg → 17.2 mg maximum based on response and tolerability (Foundayo label)
- Take any time of day, with or without food, with or without water
- If you miss 7 or more doses in a row, the label says to restart escalation at a lower dose
ATTAIN-1 Trial: Obesity Data
In the ATTAIN-1 Phase 3 obesity trial of adults with overweight or obesity:
- 17.2 mg dose: 11.1% mean body weight loss at 72 weeks vs 2.1% placebo (Foundayo label)
- 9 mg: 8.3%; 5.5 mg: 7.4%
- Trial papers report capsule doses (6, 12 and 36 mg). Lilly says the 36 mg capsule corresponds to the 17.2 mg tablet and 12 mg to 9 mg, so "36 mg" results describe the top marketed dose, not a higher one
Head-to-Head vs Oral Semaglutide
The most-cited 2026 data point comes from a Lancet-published Phase 3 trial (ACHIEVE-3, February 26, 2026) of 1,698 adults with type 2 diabetes on metformin, randomized to orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, or oral semaglutide 14 mg for 52 weeks:
| Endpoint | Orforglipron 36 mg | Oral semaglutide 14 mg |
|---|---|---|
| A1C reduction | ~1.9–2.0 percentage points | ~1.5 percentage points |
| Weight loss | ~8.2% (~20 lb) | ~5.3% (~11 lb) |
| Treatment discontinuation for side effects | ~9.7% | ~4.9% |
Orforglipron won on both A1C and weight, but at the cost of more GI side effects and dropouts. The trial's 36 mg capsule matches today's 17.2 mg Foundayo tablet, and its oral semaglutide comparator was Rybelsus, whose 14 mg dose now corresponds to Ozempic tablets 9 mg.
Side Effects and Drug Interactions
- GI symptoms (nausea, vomiting, diarrhea) dominate — comparable to injectable GLP-1s
- Treatment discontinuation due to side effects: ~9% in head-to-head trial
- Can interact with simvastatin and other drugs affected by absorption rate
- May reduce oral contraceptive effectiveness: the label advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase
Mechanism
Endocrinologist Dr. Rozalina McCoy describes orforglipron as a molecule that "absorbs more readily in the gut without breaking down in the stomach." Small molecule structure (vs. peptide) is the structural difference that enables flexible dosing.
Oral Wegovy (Oral Semaglutide for Weight Loss)
Novo Nordisk's high-dose oral semaglutide, approved December 22, 2025 specifically for chronic weight management and launched in the US on January 5, 2026.
Dosing
Strict titration:
- Start at 1.5 mg daily for 30 days
- Step up every 30 days: 4 mg → 9 mg → 25 mg target (Wegovy label)
Administration rules:
- Take first thing in the morning on a completely empty stomach
- Swallow with no more than 4 oz (120 mL) of plain water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
Trial Results
OASIS-4 and related Phase 3 trials produced:
- 25 mg pill over 64 weeks (OASIS 4): mean weight loss 13.6% (vs 2.4% placebo) in the label's intention-to-treat analysis; Novo reports 16.6% for people who kept taking it
- OASIS 1 showed 15.1% mean loss (vs 2.4% placebo) at 68 weeks, but that was a 50 mg dose that is not the approved product
- The matching Wegovy injection drives ~15% mean weight loss in similar trials
Side Effects
- Same GI side-effect profile as the injectable: nausea, vomiting, diarrhea, constipation
- In OASIS 4, 6.9% of people on the 25 mg pill stopped because of side effects vs 5.9% on placebo, mostly for GI reasons
- Serious risks: thyroid C-cell tumor signal (boxed warning), pancreatitis, gallbladder, kidney injury, vision changes, diabetic retinopathy
The Empty-Stomach Trap
The 30-minute fast is the real-world problem. Patients on levothyroxine, omeprazole, warfarin, or any morning medication with strict timing have to plan carefully. Mistiming weakens absorption — and missed doses can't be made up the same day.
Breastfeeding Contraindication
Animal studies showed SNAC presence in breast milk. The FDA label states: "advise patients that breastfeeding is not recommended during treatment with [oral Wegovy]." This is stricter than the injectable because of the SNAC component.
Rybelsus
The original GLP-1 pill — approved in September 2019 for type 2 diabetes only. Same molecule as oral Wegovy, but the dose range tops out at 14 mg, which is well below the 25 mg weight-loss ceiling. In the US, Rybelsus is being discontinued: wholesaler shipments stopped from May 2026, and pharmacies are dispensing remaining stock, which has been limited since about July 2026. Ozempic tablets replace it, and some payers transferred Rybelsus prior authorizations automatically.
Dosing
- R1 (original) formulation: 3 mg → 7 mg → 14 mg daily
- R2 (newer) formulation: 1.5, 4, 9 mg — now sold as Ozempic tablets (approved February 4, 2026); switch Rybelsus 7 mg to 4 mg and 14 mg to 9 mg, not mg-for-mg (label)
- Same empty-stomach + 30-minute fast rule as oral Wegovy (unchanged for Ozempic tablets)
Efficacy
- A1C reduction: ~1.0–1.5 percentage points at the 14 mg dose
- Weight loss: typically 4–7 lb over 6 months as a secondary effect
- Not approved for weight management — though prescribed off-label by some clinicians
Cost
These figures apply to remaining Rybelsus stock. For new US prescriptions, Ozempic tablets are self-pay from $149/month at NovoCare Pharmacy, and Novo's $25 savings offer covers eligible commercially insured patients.
- List price: $1,027.51/month
- Often well-covered by insurance for type 2 diabetes
- $25/month with the Novo Nordisk savings card for some commercially insured patients
Pill vs Injection: The Trade-Offs
| Pills | Weekly injections (Wegovy, Zepbound) | |
|---|---|---|
| Top-dose weight loss (1+ year) | ~12–14% | ~15–22% |
| Dosing frequency | Daily | Weekly |
| Needle? | No | Yes |
| Food/water rules | Strict (sema) or none (orforglipron) | None |
| Storage | Room temperature | Refrigerated until use |
| Bioavailability | ~1% (sema), higher (orforglipron) | ~80% subcutaneous |
| Out-of-pocket starting price | $149/month (Wegovy pill) | $199–$349/month |
| Manufacturer savings card | Down to $25/month for many | Down to $25/month for many |
| Missed-dose flexibility | Skip; resume next day | Take within 2 days of scheduled date |
| Travel friendliness | High | Lower (refrigeration concerns) |
Dr. Melanie Jay sums up a real benefit: "One of the benefits of the pill is that you don't have to refrigerate it and advertise you're on medication." Dr. W. Timothy Garvey adds: "It's easier to use and store the oral pill. You can travel with it and not worry about refrigeration."
The counterargument from Dr. Jay: "Patients get used to taking something once per week. I think weekly dosing leads to better adherence than daily pills."
How Effective Are the Pills, Really?
A 2025 retrospective observational study (105 adults, 2019–2022) compared GLP-1 injection users to pill users:
- Injection: 5.26 kg lost
- Pill: 3.64 kg lost
- Authors concluded the difference was "not clinically significant"
In randomized trials at top doses, the difference is larger — the injectable form has about 80% bioavailability vs ~1% for oral semaglutide, which is why pill doses are roughly 10x higher in mg terms.
Pricing (May 2026)
| Medication | List price | Self-pay starting price | With savings card |
|---|---|---|---|
| Foundayo (orforglipron) | ~$1,300/month estimated | ~$149/month starting | ~$25 with commercial insurance |
| Oral Wegovy 1.5 mg | $1,349.02 | $149/month | $25/month for many |
| Oral Wegovy 9–25 mg | $1,349.02 | $299/month | $25/month for many |
| Wegovy injection | $1,349.02 | $199 (first 2 mo), then $349 | $25/month for many |
| Ozempic tablets (Nov 2026) | — | from $149/month (NovoCare) | $25/month for many |
| Rybelsus (being discontinued in the US) | $1,027.51 | not widely cash-priced | $25/month for many |
Medicare Part D coverage for weight-loss indications remains patchy. Diabetes use (Ozempic tablets, which replace Rybelsus) is reimbursed much more reliably than obesity use. Foundayo is not approved for type 2 diabetes as of November 2026; its July 2026 label covers weight management only. Our guide to where to buy oral semaglutide compares each pill and the routes people use to pay for it.
Who Can Take a GLP-1 Pill
Eligibility for oral Wegovy and Foundayo:
- BMI ≥30, OR
- BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, OSA, cardiovascular disease)
Standard contraindications apply to all three:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2 (MEN2)
- Prior serious hypersensitivity to a GLP-1 receptor agonist
- Pregnancy (stop at least 2 months before trying to conceive)
- Active breastfeeding — especially relevant for oral semaglutide given SNAC
Side Effect Comparison
| Side effect | Oral semaglutide | Orforglipron | Notes |
|---|---|---|---|
| Nausea | Common, especially during titration | Common, slightly higher rates | Both fade over weeks |
| Vomiting | Common at higher doses | Slightly more frequent | Worse with high-fat meals |
| Diarrhea | Common | Common | Often resolves |
| Constipation | Common | Common | Fiber + hydration help |
| Decreased appetite | Frequent (often a goal) | Frequent | Watch protein intake |
| Headache, fatigue, dizziness | Reported | Reported | Mostly mild |
| Treatment discontinuation | ~5–7% | ~9–10% | Higher rate for orforglipron |
Both pills carry the same boxed warnings as the injectable forms (thyroid C-cell tumors, pancreatitis risk, gallbladder, vision changes). For the buying side, see our guide to tirzepatide pills where to buy, including what to check on any listing.
How to Decide Between Them
| If your priority is… | Likely best pill |
|---|---|
| Maximum weight loss at any cost | Oral Wegovy 25 mg or Foundayo 17.2 mg |
| No food or timing restrictions | Foundayo |
| Lowest barrier to start cheap | Oral Wegovy 1.5 mg with savings card ($25/month) |
| Diabetes-first treatment | Ozempic tablets (replacing Rybelsus in the US) |
| Best tolerability profile | Oral semaglutide (slightly lower discontinuation) |
| Travel-friendly, no refrigeration | Any pill — but Foundayo wins for no rules |
What People Get Wrong About GLP-1 Pills
- "The pill is the same as the shot." Same drug class, but oral semaglutide has ~1% bioavailability vs ~80% for the injection. Pill doses are roughly 10x higher in mg.
- "Rybelsus is approved for weight loss." It is not, and neither are Ozempic tablets, its US replacement. Only oral Wegovy and Foundayo carry the weight-loss indication.
- "GLP-1 pills you can buy online without a prescription are real." Patches, drops, gummies, and "GLP-1 booster" supplements are not pharmaceutical GLP-1 agonists.
- "Side effects are milder because it's a pill." Trial data actually show higher GI side effect rates with oral semaglutide than injection because of higher peak daily concentrations.
- "Foundayo is just a stronger Wegovy." Different molecule entirely — small molecule, not a peptide. Different drug-interaction profile.
Frequently Asked Questions
What is the best GLP-1 pill for weight loss? For maximum weight loss, oral Wegovy at 25 mg (13.6%) and Foundayo at 17.2 mg (11.1%) are the top FDA-approved options. Foundayo wins on convenience because it has no food restrictions.
How quickly does the GLP-1 pill work? Appetite and food noise typically quiet within the first 1–2 weeks. Measurable weight loss usually starts in weeks 2–4, with the biggest changes during months 3–9.
Can I take a GLP-1 pill with coffee or food? Only Foundayo. Oral Wegovy, Ozempic tablets and Rybelsus require a fully empty stomach with no more than 4 oz of plain water, plus a 30-minute fast before anything else.
Is the GLP-1 pill cheaper than the injection? At the starting dose, yes — oral Wegovy is $149/month vs $199–$349/month for the injection. At the top dose, prices converge. Insurance and savings cards can drop either to $25/month.
Do GLP-1 pills cause the same side effects as Ozempic? Yes, the same profile — nausea, vomiting, diarrhea, constipation. Oral forms actually show slightly higher GI rates in some trials due to higher peak daily concentrations.
Can I buy a GLP-1 pill over the counter? No. Every FDA-approved GLP-1 pill requires a prescription. Patches, gummies, drops, and "GLP-1 booster" supplements sold OTC do not contain real GLP-1 agonists.
How long does semaglutide stay in my system after stopping the pill? Semaglutide remains active for approximately 5 weeks after the final dose. Plan for that washout if pregnancy or surgery is upcoming.
Is there a tirzepatide pill? No. No oral tirzepatide is FDA-approved. Foundayo, also from Eli Lilly, is a different GLP-1-only molecule.
Is Rybelsus still available? In the US it is being discontinued, and pharmacies can fill only remaining stock. Ozempic tablets replace it: Rybelsus 7 mg switches to 4 mg, and 14 mg to 9 mg. Outside the US, Rybelsus is still sold.
Can I take the Ozempic pill for weight loss? It is not approved for weight loss; Ozempic tablets top out at 9 mg for type 2 diabetes. The weight-loss semaglutide pill is the Wegovy pill, up to 25 mg.
Last reviewed: November 4, 2026
Sources
- GLP-1 Weight-Loss Pills: What You Need to Know — Yale Medicine
- The New GLP-1 Pill: Everything You Need to Know in 2026 — Healthline
- Everything You Need to Know About the GLP-1 Pill — Medical News Today
- GLP-1 Pill vs Shots: What to Consider — WebMD
- Head-to-head trial shows Lilly's orforglipron outperforms oral semaglutide — Scientific American
- Lilly's GLP-1 pill tops Novo's Rybelsus in head-to-head trial — BioPharma Dive
References
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Patients With Type 2 Diabetes. Diabetes Care. 2019. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021. PubMed
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. NCBI Bookshelf. NCBI Bookshelf
